Loading song details...
Robert M Rifkin MD FACP Explains How Isatuximab Differs From Daratumumab
No description available.
MP3 Download
Video Download
Related Songs
1:11
Robert M Rifkin MD On How The Connect Multiple Myeloma Patient Registry Is Helping Patients
1:17
Robert Rifkin MD Discusses The Rationale For Genetically Profiling AML Patients
1:03
Robert Rifkin MD Talks About What Clinical Data Could Change The Way Multiple Myeloma Is Treated
1:36
Clinical Trial INSIGHT With Robert Rifkin MD Rocky Mountain Center
1:09
Robert Rifkin MD Discusses The Outcomes Of TOURMALINE MM3 Study
1:15
Robert M Rifkin MD FACP Considers Progression Free Survival In MM When Treating With Isatuximab
1:49
Robert M Rifkin MD FACP Discusses Outcomes From The ECOG Trial In Smoldering Multiple Myeloma
0:31
Robert Rifkin MD Explains The Key Features Of Biosimilars
1:20
Robert Rifkin MD Shares His Thoughts On If A Rituximab Biosimilar Can Replace
1:37
Robert M Rifkin MD FACP Discusses Maintenance Regimens For Multiple Myeloma
1:41
Robert M Rifkin MD FACP Speculates On The Promise Of Bispecific Antibodies In MM
0:47
Robert Rifkin MD Explains Whether Or Not Anti BCMA CAR T Cell Therapy Looks Promising
1:27
Robert Rifkin MD On The Hurdles That Might Prevent Adoption Of Biosimilars By Oncologists
1:33
Robert Rifkin MD Lists Those Biosimilars Now Approved Or Close To Approval For Cancer Patients
0:42
Robert M Rifkin MD On The Connect Multiple Myeloma Patient Registry Improving Characterization
0:49
Robert M Rifkin MD On Excluding Transplantation From MM Treatment Algorithms
0:52
Robert Rifkin MD Tells Us About Biosimilar Pricing And Reimbursement
1:04
Robert M Rifkin MD Discusses If COMPASS Is Close To Its Goal Of Achieving Whole Genome Sequencing
2:04
MM 6 Trial In Class Transition To Ixazomib Newly Diagnosed Myeloma Robert Rifkin MD ASH24
2:28